Celanese Targets $800 Million Free Cash Flow by 2025

Published 11 hours agoCE

Celanese Targets $800 Million Free Cash Flow by 2025

Celanese Corporation has set its sights on generating between $700 million to $800 million in free cash flow by 2025. This ambitious target will be pursued through a series of strategic initiatives focused primarily on cost reductions and divestitures. As part of this effort, Celanese has already achieved over $75 million in cost-saving measures, mainly within selling, general, and administrative expenses. Furthermore, the company plans to reduce its 2025 capital expenditure budget to $300-$350 million—a $100 million cut from prior projections, according to a report on GuruFocus.

In addition to cost-cutting, Celanese is also refining its assets through divestitures. A significant move includes the closure of its Luxembourg Mylar Specialty Films manufacturing operations, a joint venture with Teijin. This step is part of a broader strategy to exit higher-cost facilities and enhance productivity, as noted by MarketScreener. The company continues to pursue other divestitures, aiming to improve its operating model and better align with strategic objectives.

As Celanese navigates these changes, a renewed focus on leadership and productivity emerges. They have appointed Todd Elliott to lead the Engineered Materials division and brought on Chris Kean and Scott Sutton to its Board of Directors. The company emphasizes key areas such as cash generation, margin expansion, and productivity to bolster shareholder value. GuruFocus highlights that Celanese is optimistic about increasing its free cash flow in 2025, thanks to better working capital management, lower cash taxes, and reduced capital expenditures.

Share this article

Twitter Facebook LinkedIn

Recent Articles

PTC Therapeutics Forecasts Up to $800 Million in 2025 Revenues

PTC Therapeutics Forecasts Up to $800 Million in 2025 Revenues

8 minutes agoPTCT

PTC Therapeutics has announced its financial expectations for 2025, projecting total revenues between $600 million and $800 million. This forecast includes income from existing products, new product launches, and royalties from Evrysdi. As part of its broader business strategy, the company is pursuing a robust product pipeline expected to support these revenue goals. The pharmaceutical company's anticipated expenses for 2025 are substantial, with expected GAAP R&D and SG&A costs ranging between $805 million and $835 million. In non-GAAP terms, which exclude estimated non-cash stock compensation of $75 million, these expenses are expected to be between $730 million and $760 million. Reuters reported that these figures reflect PTC's substantial investment in research and development and its strategic operational initiatives. PTC's recent collaboration with Novartis marks a significant achievement. Closing a licensing agreement for the PTC518 Huntington's disease program has provided an immediate $1.0 billion boost, with further milestone payments of up to $1.9 billion possible. Additionally, PTC stands to gain a 40% profit share from U.S. sales and enjoy tiered royalties outside the U.S. This partnership has significantly improved PTC's financial standing, leaving the company with a cash position over $2.0 billion as of January 2025, thus positioning it strongly for future endeavors.

Mercury Systems Projects Strong Free Cash Flow for FY25

Mercury Systems Projects Strong Free Cash Flow for FY25

23 minutes agoMRCY

Mercury Systems is setting a confident tone for its fiscal year 2025, projecting that its free cash flow will surpass previous expectations, fueled by enhanced margins and operational improvements. In a promising display of financial health, the company reported a record free cash flow of $81.9 million for the second quarter of FY25, markedly up from $37.5 million in the same period a year earlier. The boost in free cash flow is backed by a 19.5% year-over-year reduction in net working capital, highlighting Mercury's strides in operational efficiency. Reuters noted these improvements as a significant driver behind the company's optimistic financial outlook. CEO Bill Ballhaus shared his positive perspective, attributing Mercury's potential growth to strategic business maneuvers that promise consistent organic expansion, healthier margins, and solid free cash flow. This optimism underscores Mercury Systems' dedication to maintaining its upward trajectory in FY25.

Enbridge, I Squared, and MPLX Secure Major Stake in Matterhorn Pipeline

Enbridge, I Squared, and MPLX Secure Major Stake in Matterhorn Pipeline

38 minutes agoENB

Enbridge Inc., I Squared Capital, and MPLX LP have successfully agreed to secure up to an 85% stake in the Matterhorn Express natural gas pipeline. This acquisition involves a strategic ownership structure where WhiteWater Midstream, supported by I Squared Capital and First Infrastructure Capital, will control up to 65% of the pipeline. Enbridge and MPLX are each set to own a 10% share. According to Reuters, these stakes have been acquired from Ridgemont Equity Partners and Devon Energy Corp. The Matterhorn Express pipeline is an extensive infrastructure spanning 580 miles, capable of transporting up to 2.5 billion cubic feet of natural gas daily. It moves vital resources from the productive Permian Basin in West Texas and New Mexico straight to the outskirts of Houston. The entire operation has been valued at over $5 billion, which includes existing debt. Additionally, MPLX announced it has separately acquired a further 5% interest in the pipeline joint venture, amounting to $151 million. Having commenced operations in October 2024, the Matterhorn pipeline plays a crucial role in easing bottlenecks and enhancing local gas price conditions. This, in turn, has supported increased oil production across the United States, particularly impacting the shale sectors. These recent developments highlight the ongoing strategy of Enbridge, I Squared Capital, and MPLX to expand their influence and capability in the natural gas market.

Aviat Networks Aims for $140 Million Pasolink Milestone by 2025

Aviat Networks Aims for $140 Million Pasolink Milestone by 2025

53 minutes agoAVNW

Aviat Networks is making strides toward achieving a $140 million annual run rate for its Pasolink business by the end of fiscal year 2025. In its fiscal 2025 second quarter, the company reported receiving over $35 million in Pasolink orders, showing a robust growth trend that supports its ambitious target. Integration of the Pasolink business is progressing well with Aviat focusing on cost optimization and profitability improvements. The business was nearly breakeven on an EBITDA basis in the past quarter and contributed positively to free cash flow, as noted by Investing.com. These efforts are crucial as Aviat enhances its ability to meet its financial goals. Amidst its efforts with Pasolink, Aviat is also planning strategic expansions, particularly by delivering private network offerings in Indonesia and launching new products in India between March and June next year. Financially, the company continues to project confidence, maintaining its full-year revenue guidance between $430 million and $470 million, and forecasting adjusted EBITDA between $30 million and $40 million.